Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 7 December 2025 - 10 December 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

December 10, 2025 – New York / Tel Aviv Teva Pharmaceutical Industries Limited (NYSE: TEVA; TASE: TEVA) is trading around its 52‑week highs as a wave of fresh news hits the stock: a new U.S. FDA filing for a once‑monthly schizophrenia drug, a string of bullish analyst upgrades, stronger long‑term cash‑flow guidance and notable institutional activity. At around $29 per share, Teva now carries a market capitalization of roughly $32–33 billion, with a 12‑month trading range of approximately $12.5 to just over $29.MarketBeat+2MarketBeat+2 Against that backdrop, investors are trying to decide whether TEVA is simply “priced for the pivot” or
10 December 2025
··
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Updated: December 10, 2025 Key takeaways LLY stock today: price, performance and valuation snapshot As of mid‑day trading on December 10, 2025, Eli Lilly (NYSE: LLY) is changing hands at around $980 per share, down slightly on the day and just below its recent all‑time high above $1,050. That price values Lilly at roughly $930–$1,000+ billion in market cap, depending on intraday moves, placing it in the same league as mega‑cap tech giants and making it the first healthcare company ever to cross the $1 trillion mark. Reuters Year to date, Reuters reports that LLY shares are up more than
10 December 2025
··
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is back on traders’ radar as a late‑stage CNS biotech preparing for a potential New Drug Application (NDA) in schizophrenia while its stock trades under $1 and analysts publish double‑ and even triple‑digit upside targets. As of mid‑session on December 10, 2025, RVPH is trading around $0.69 per share, up roughly 10% on the day, implying a market capitalization of about $78–80 million.Simply Wall St That price sits near the low end of its 12‑month range of roughly $0.25 to $3.00, with the share price still down more than 70% over the past year
10 December 2025
··
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options. StockInvest+2MarketWatch+2 This article looks at where BDRX stock stands on December 10, 2025, the latest clinical and regulatory news from Biodexa, the company’s increasingly complex capital structure, and how third‑party models and analysts are framing the risk–reward profile into 2026.
10 December 2025
··
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price sits near multi‑year highs after a year of strong earnings and upgraded guidance.Stock Titan+1 Below is a deep dive into today’s news, how GSK shares are trading, what analysts are forecasting, and where the risk/reward balance looks to be heading into 2026. This is information, not personalised investment advice. GSK share price today: still near the top of its 2025
10 December 2025
···
Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Note: This article is for informational purposes only and does not constitute investment advice. Merck stock recap: What happened on December 9, 2025? Merck & Co., Inc. (NYSE: MRK) closed Tuesday, December 9, 2025 at $96.89, down 2.06% on the day, after trading between an intraday low of $96.06 and a high of $99.85. Volume was elevated at about 15.3 million shares, above recent averages, signaling active institutional and trader participation.StockAnalysis In after-hours trading, Merck ticked slightly higher to $96.91 around 7:04 p.m. ET, essentially flat versus the close and suggesting no major new company‑specific headline hit the tape after
10 December 2025
··
Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

HUNTSVILLE, Ala. — December 9, 2025 Eli Lilly and Company will invest more than $6 billion in a new advanced pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 high‑value permanent jobs and an estimated 3,000 construction jobs in what state leaders are calling the largest initial private industrial investment in Alabama history. City of Huntsville+2governor.alabama.gov+2 The facility, planned for a 260‑acre site at the northeast corner of I‑565 and Greenbrier Parkway in Huntsville‑Limestone County, will manufacture active pharmaceutical ingredients (APIs) for small‑molecule and peptide medicines, including orforglipron, Lilly’s first oral GLP‑1 obesity drug now heading toward global regulatory submissions. City
10 December 2025
·
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) has quietly turned into one of 2025’s wilder biotech stories: a tiny oncology name that’s run more than eightfold off its 52-week low, pulled back on a big equity raise, and now sits in the middle of a high-stakes bet on a single breast-cancer drug. Below is a structured look at OLMA stock today, the latest news, Street forecasts, and the key risks investors are debating as of December 9, 2025. OLMA stock today: price, performance and volatility As of the latest trade on December 9, 2025, Olema Pharmaceuticals shares change hands at around $26–27
9 December 2025
·
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is ending 2025 in rare biotech air. The RNA interference (RNAi) specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2 As of intraday trading on December 9, 2025, Arrowhead Pharmaceuticals stock trades around $69 per share, giving the company a market value in the $9–9.5 billion range. That’s up dramatically from under $10 per share at its 52‑week low, and represents a
9 December 2025
··
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

As of 9 December 2025, GSK plc (LSE: GSK; NYSE: GSK) stock is trading close to its 52‑week highs on both sides of the Atlantic, after a year in which the UK pharma group has upgraded guidance, accelerated buybacks and largely defused one of the biggest litigation overhangs in the sector. On the NYSE, GSK ADRs change hands around $48–49, very near their 52‑week high of $49.31, and up roughly 37% over the past year, versus about 14% for the S&P 500 over the same period. Yahoo Finance+1 On the London Stock Exchange, GSK trades around £18.0, also just below
9 December 2025
···
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company (NYSE: LLY) spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi to its board. At the same time, intensifying competition and price cuts in the weight‑loss drug market kept pressure on the stock. By the closing bell, Lilly shares were trading just under the psychologically important $1,000 level, still near a trillion‑dollar valuation but roughly 10% below recent highs. StockAnalysis Key takeaways for LLY before the December 9, 2025 open How
9 December 2025
······
Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer Inc. (NYSE: PFE) is back in focus on December 8, 2025, as investors digest fresh clinical data in hemophilia, big strategic bets in obesity drugs, and an aggressive, AI‑driven cost‑cutting program – all while the stock continues to trade at a high dividend yield and a discount to many Big Pharma peers. As of Monday morning, Pfizer shares are trading around $26 per share, slightly lower on the day and roughly in the middle of their 52‑week range of $20.92–$27.69. That range implies a market capitalization of about $148 billion, a price‑to‑earnings (P/E) ratio near 15x, and relatively low
8 December 2025
··
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase (BTK) degrader bexobrutideg (NX‑5948) in blood cancers at the American Society of Hematology (ASH) Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat+3GlobeNewswire+3GlobeNewswire+3 The rally comes barely two months after Nurix posted a weak third quarter and executed a large equity raise, underscoring how heavily sentiment in this name is tied to the clinical trajectory of its degrader pipeline. ChartMill+2StockAnalysis+2 NRIX stock today: price
8 December 2025
··
Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Published: December 8, 2025 – This article is for informational purposes only and is not financial advice. Key Takeaways JNJ Stock Today: Price, Performance and Dividend Johnson & Johnson (NYSE: JNJ) is trading around $202–203 per share in New York trading on December 8, 2025. Recent closing data show the stock finished at $202.48 on December 8 after a modest decline of 0.27%.StockAnalysis Over the past year, JNJ has staged a strong recovery: This rally has been strong enough that Simply Wall St describes 2025 as a “40.6% rally” year and still concludes the stock screens as undervalued on both
8 December 2025
··
Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached in late November. That pullback comes after a powerful rebound from a May low near $76, driven by excitement over new cardiovascular and respiratory drugs, plus a $9.2 billion flu‑drug acquisition — even as investors remain focused on the looming 2028 patent cliff for Keytruda and fresh regulatory headwinds.Finviz+2Reuters+2 Below is a detailed, news‑ready rundown of today’s key headlines, stock
8 December 2025
··
Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis (FAP). The news gives investors something they’ve been waiting on for years: early clinical proof that Recursion’s AI‑driven platform might actually work in real patients. GlobeNewswire+1 Shares of Recursion (ticker: RXRX) traded in the mid‑$4 range on Monday, up low single digits intraday after jumping as much as around 6% in pre‑market trading on the back of the data, according to Reuters and Benzinga. Reuters+1 Below
8 December 2025
···
Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

As Wall Street gears up for the opening bell on Monday, December 8, 2025, Merck & Co., Inc. (NYSE: MRK) enters the week at a pivotal moment. The Dow component has rallied hard in recent months, but now faces a mix of powerful growth catalysts and fresh legal and financing questions that could shape the next leg of its move. On Friday, December 5, Merck shares slipped 1.16% to $99.72, marking a second straight daily loss and modest underperformance versus the broader market. The stock is still only about 6% below its 52‑week high of $105.84, set on November 25,
8 December 2025
·
Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

As Wall Street heads into Monday’s session, Eli Lilly and Company (NYSE: LLY) sits at the center of several big storylines: Chinese market access for its Alzheimer’s drug, a fresh FDA decision and new data for cancer therapy Jaypirca, price cuts for blockbuster obesity drug Zepbound, and a wave of institutional positioning. Below is a structured look at what matters for Eli Lilly stock before the U.S. market opens on Monday, December 8, 2025. 1. Where LLY Stock Stands After a Choppy Week In short, LLY heads into Monday as a mega‑cap growth stock that has cooled slightly but still
7 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Updated: December 7, 2025 – For informational purposes only, not investment advice. 1. VRTX stock snapshot as of early December 2025 Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy—and volatile—2025. As of the close on Friday, December 5, 2025, VRTX shares finished around $455.48, giving the company a market value in the $115–117 billion range.Stock Titan+3MacroTrends+3StockInvest+3 Key numbers investors are watching right now: Technically, several short‑term models still classify VRTX as a “buy or hold candidate”: StockInvest.us, for example, highlights a strong short‑term uptrend, with the price up almost 8% over the past two weeks and an estimated 3‑month target
7 December 2025
··
Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt offering, secured fresh regulatory wins in its cardiopulmonary and animal-health franchises, boosted its dividend, and simultaneously ran into a new patent roadblock for its subcutaneous Keytruda injection in Germany. PR Newswire+4Wikipedia+4Stock Titan+4 Against that backdrop, MRK stock is trading near the top of its 52‑week range, and Wall Street is sharpening its forecasts for 2026 and beyond. MRK stock price
7 December 2025
···
1 … 23 24 25 26 27 … 34

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop